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Abstract: In the face of excellent survival rates for pediatric and adolescent cancer, 
preserving the opportunity to have biological children is an important component of long 
term quality of life. Yet, modern chemotherapeutic regimens continue to pose a threat to 
fertility. The only fertility preservation methods available to pre-pubertal children of both 
genders is cryopreservation of gonadal tissue, a highly experimental intervention, or 
shielding/re-location of reproductive tissue in the setting of radiation. These techniques are 
available in the post pubertal population as well, but post pubertal patients also have the 
option for cryopreservation of gametes, a process that is much simpler in males than 
females. For this reason, prior to the initiation of therapy, sperm banking should be 
considered standard of care for males, while consideration of embryo or oocyte 
cryopreservation should be limited to those females at risk of developing ovarian failure. 
Attention to reproductive health and fertility preservation should continue after the 
completion of therapy. Establishing programs that streamline access to current fertility 
preservation techniques will assist in ensuring that all eligible patients can avail themselves 
of current options. 
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1. Introduction 
The refinement of therapeutic interventions and supportive care has resulted in cure rates upwards 
of 80% in children and adolescents diagnosed with cancer, with subsequent estimates that 1 in 530 
young adults between the ages of 20 and 39 is a survivor of a childhood cancer [1]. It has long been 
recognized that toxicities from cancer directed therapy arising during treatment could be permanent 
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and that new complications could manifest well into the future [2]. These complications include 
damage to the reproductive system in both males and females resulting in impaired fertility [3,4]. 
Newly diagnosed patients, survivors of childhood and adolescent cancer, and their families have 
identified that the retention of fertility is an important aspect of their lives [5,6], and note high levels of 
distress with loss of fertility [7]. Advances in the field of reproductive endocrinology have increasingly 
offered the opportunity for the preservation of fertility in those at risk [8]. Multiple organizations 
internationally have recommended that, at a minimum, all individuals of reproductive age receive 
information about fertility risk, options for fertility preservation and referrals to the appropriate health 
care providers [9–16]. Yet, putting these recommendations into practice has remained a challenge. 
Despite the establishment of the field of oncofertility, a recent survey that compared recollections of 
discussions of fertility at diagnosis found static rates of discussion in 2004 and 2011, 60% vs. 57% 
respectively for males and 50% vs. 45% for females. In addition, while males who had discussions 
about fertility were satisfied with the content of those discussions, females were not [17]. 
Studies of health care professionals have also suggested that risks for infertility are not routinely 
discussed [18]. Reasons include lack of knowledge or training on the subject, language/cultural 
barriers between the patient and the physician, the perception that fertility preservation discussions add 
stress to cancer patients’ situation, general uncertainty about the success of fertility preservation 
methods or patient ability to afford fertility preservation, concerns about patients with a poor prognosis 
or late stage disease not being appropriate candidates for fertility preservation [19], concerns about 
information “overload” [20] and concerns about delaying the start of treatment [21]. Similar to the 
patient experience described above, practitioners surveyed have described that they are more likely to 
discuss and refer a male patient for fertility preservation than a female patient [21]. 
Providing fertility preservation support in this population requires prior knowledge of who is at risk 
and what options are available and having an infrastructure in place for patient counseling and referral. 
Institutional programs that systematically address this issue have begun to be implemented [22] in  
an effort to meet the recommendations of the guidelines cited above. This article will summarize risks 
for infertility and options for preservation in male and female patients diagnosed with a childhood cancer. 
2. Fertility Preservation in Females 
2.1. Risk for Infertility 
Paramount in importance when considering infertility risks in females is that their full reserve of 
oocytes are present at birth and are depleted over time. At the onset of puberty, approximately 400,000 
follicles remain within the ovaries. Through menstruation, atresia and apoptosis a progressive decline 
in ovarian primordial follicles continues during a healthy woman’s reproductive lifespan.  
Since fertility is related to the number of oocytes present at a given time, fertility begins to wane when 
a woman reaches her late 20s, drops more significantly in the mid to late 30’s and is no longer  
a possibility following menopause [23]. 
Cancer directed treatment can cause depletion of the existing oocyte reserve. Alkylating agents, 
particularly cyclophosphamide and procarbazine [24], and heavy metals have been found to be the 
chemotherapeutic agents most highly toxic to the ovary. Higher cumulative doses and older age at 
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treatment are both associated with greater toxicity [25]. The effect of age is presumably related to the 
smaller number of follicles in the ovaries of older patients at the time of treatment. Direct irradiation of 
the ovaries, by pelvic or spinal irradiation, in the 1–2 Gy dose range, can have permanent effects by 
causing the depletion of follicles, even in young girls [26]. The Children’s Oncology Group (COG) 
long term follow-up guidelines include exposure to higher cumulative doses or combinations of 
alkylators, specifically busulfan >600mg/m
2
, cyclophosphamide >7.5 g/m
2
, or conditioning for 
transplant, prepubertal gonadal irradiation of ≥10 Gy, pubertal gonadal irradiation of ≥ 5 Gy, and 
alkylators in combination with irradiation of the abdomen/pelvis, lumbar or sacral spine, or total body 
irradiation (TBI) as risk factors for hypogonadism [27]. There is some emerging evidence that ovarian 
reserve may already be diminished at diagnosis [28]. 
The degree to which treatment depletes the ovarian reserve contributes to the length of the 
reproductive window that remains for a given patient. If the treatment related depletion approaches the 
threshold for menopause this is referred to as acute ovarian failure (AOF). If the reserve is diminished, 
but not exhausted from treatment, then the individual may remain fertile following therapy but have  
an overall shortened reproductive lifespan, referred to as premature menopause (PM). With the 
exception of patients who receive very high dose chemotherapy as part of conditioning regimens for 
stem cell transplants, particularly in conjunction with radiation, young female cancer patients generally 
have a greater risk of developing PM than AOF. The Childhood Cancer Survivor Study (CCSS) 
identified AOF, assessed as self-reported amenorrhea, in 6.3% of survivors surveyed, the majority of 
whom had received abdominal or pelvic radiation [29]. In the CCSS non-surgical PM was 13 times higher 
among survivors than sibling controls. Risk factors included attained age, exposure to increasing doses 
of alkylating agents, radiation to the ovaries and a diagnosis of Hodgkin Lymphoma [30]. 
Radiation therapy may also impact fertility by causing damage to the uterus thereby limiting the 
ability of a survivor to carry a pregnancy to term. Lower birth weight [4], stillbirth and neonatal death [31] 
have been reported to occur more frequently in women previously treated with pelvic irradiation. 
Hysterectomy or oophorectomy has obvious implications for preservation of fertility. Doses of cranial 
radiation of 35–40 Gy or greater can cause hypogonadism by impacting the hypothalamus and 
pituitary [32]. Doses of radiation in the range of 22–27 Gy directly to the hypothalamus/pituitary have 
resulted in decreased hazard ratio for pregnancy in the CCSS cohort [33]. 
2.2. Options for Fertility Cryopreservation 
2.2.1. Oocyte and Embryo Cryopreservation 
Embryo and oocyte cryopreservation are both considered non-experimental options for fertility 
preservation in post pubertal females, with oocyte cryopreservation having achieved this designation 
by the ASRM in 2012 [34]. This change in status removes what had previously been a barrier for 
fertility preservation in adolescents as there is no requirement for partner or donor sperm. Both 
interventions involve controlled ovarian stimulation of the ovaries to produce multiple mature oocytes. 
Oocytes are subsequently retrieved transvaginally in a procedure that, while minimally invasive, 
requires sedation or anesthesia. In oocyte cryopreservation the oocytes are cryopreserved following 
their extraction. In embryo cryopreservation the mature follicles are fertilized in vitro with partner or 
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donor sperm and then cryopreserved. When fertility is desired in the future the oocytes or embryos are 
thawed. Embryos are placed through the cervix into the uterus, either of the patient themselves or of a 
gestational surrogate, if the patient’s uterus is compromised. IVF with frozen embryos has been widely 
studied and evaluated in the general population; live birth rates per embryo transferred are estimated at 
30%–40% [9], rates specific to individual clinics can be found for example at the Society for Assisted 
Reproductive Technologies [35] in the United States, and the Human Fertility and Embryology 
Authority [36] in the United Kingdom. Oocytes are fertilized with partner or donor sperm and then 
implanted. Nine hundred live births using frozen oocytes have been reported as of 2009 with no 
increase in congenital malformations [37]. Improvements in the freeze/thaw process have resulted in 
success rates only slightly lower than with embryos [9]. Data on the success of these procedures 
specifically in adolescent cancer patients is scarce. The disposition of unutilized cryopreserved 
oocytes, either in the setting of excess sample, lack of need, or patient death may present less of an 
ethical or emotional concern to patients and families compared to embryo cryopreservation. 
While embryo and oocyte cryopreservation is technically possible as a means of preserving fertility 
for post pubertal females, a number of practical limitations exist. Of concern to both patients and 
practitioners is the need to delay the start of chemotherapy to allow for controlled ovarian stimulation 
of the ovaries. Recently protocols have begun to be developed where stimulation begins in the luteal 
(second half) of the menstrual cycle [38] and may provide a more flexible schedule for the utilization 
of hormonal stimulation. However, depending on the urgency to begin cancer treatment, even this time 
frame may not be feasible. Cost can be a barrier although this varies greatly by country. For example, 
in the United States oocyte and embryo cryopreservation and future IVF, are expensive with costs 
upwards of $10,000 [39]. Many insurance companies do not cover these costs because cancer patients 
do not meet the definition of infertility (namely having tried to conceive unsuccessfully for greater 
than one year). Resources exist, including Sharing Hope [40], administered through Livestrong, which 
can assist with the provision of the hormone medications and discounted rates among reproductive 
endocrinologists. On the other hand, in New Zealand, for example, retrieval, fertilization if desired, 
cryopreservation, and storage of gametes and/or embryos for up to 10 years are covered by District 
Health Boards [14]. Whether sufficient time and resources exist to freeze embryos or oocytes prior to 
the start of treatment is a decision that must be reached on an individual basis between patient, parent 
and medical practitioner. 
2.2.2. Use of Gonadotropin Releasing Hormone Analogues 
The use of GnRH analogues (both agonists and antagonists) to lessen the effect of chemotherapy on 
follicular depletion has long held appeal as this is much less invasive compared to the cryopreservation 
of reproductive tissue [41]. Most early studies evaluating their efficacy have been hampered by small 
numbers, retrospective design and inconsistent outcome measures, making it difficult to draw 
definitive conclusions [42]. More recently, prospective, randomized studies have been undertaken to 
address this question. Three such studies in young adult women with breast cancer demonstrated 
decreased rates of amenorrhea in those patients who received GnRH analogues [43-45]; three trials in 
young adult patients with breast cancer [46,47] and Hodgkin lymphoma [48] demonstrated no 
protection of ovarian reserve using GnRH analogues. Two of the studies were stopped prematurely 
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when interim analyses demonstrated futility [47,48]. The 2013 ASCO guidelines recommend that 
patients be informed that there is insufficient evidence showing that ovarian suppression via the use of 
GnRH analogues protects fertility and should not be relied upon for this indication [11]. Most recently, 
the POEMS trial randomized breast cancer patients to either standardized chemotherapy or standardized 
chemotherapy plus goserelin [49]. That trial demonstrated a significant reduction in ovarian failure 
defined as amenorrhea of six months plus elevated FSH at two years. They also demonstrated  
a significantly increased odds ratio (OR = 2.22, 95% CI: 1.00–4.92, p = 0.05) for pregnancy in the 
experimental arm. This is the first study to demonstrate a difference in pregnancy rate. The impact of 
this study on future guideline recommendations remain to be seen. 
2.2.3. Ovarian Tissue Cryopreservation 
Ovarian tissue cryopreservation involves surgically removing all or a part of the cortex of the ovary, 
which contains thousands of primordial follicles. The resected tissue is cut into strips and 
cryopreserved. Because the process does not require hormonal stimulation it is the only fertility 
preservation technique that is available to pre-pubertal girls or females in whom initiation of treatment 
cannot be delayed [50,51]. Following completion of treatment the ovarian tissue can be thawed and 
transplanted orthotopically, i.e., at the site of the ovaries, or heterotopically, i.e., at another location. 
Once transplanted the follicles within the ovary have the potential to mature when appropriately 
stimulated. Approximately 30 live births have been reported utilizing this procedure of removal and 
orthotopic re-transplantation in individuals who were post-pubertal at the time of retrieval [52]. No 
births have been reported in individuals who were pre-pubescent at the time of tissue cryopreservation. 
At this time ovarian tissue cryopreservation remains highly experimental without reliable means of 
ensuring maturation of the follicles and as such should be offered within the context of an IRB 
approved protocol. In addition, there are a number of challenges that exist. Obtaining tissue requires a 
surgical procedure with anesthesia, although ideally this could be coordinated with other procedures 
required for evaluation or treatment [53]. A significant area of current research focuses on attempting 
to mature the follicles in vitro. The ability to reliably do this would allow much greater control of the 
maturation process and precludes the need to transplant tissue back into the body [54]. This is a critical 
goal as the return of ovarian tissue into the body may in fact re-introduce cancerous cells, particularly 
in hematologic malignancies [55]. 
2.2.4. Protection of Ovarian Function 
Oophoropexy, the relocation of the ovaries outside of the radiation field, may mitigate ovarian 
damage, although radiation scatter can still cause follicle depletion [56]. Shielding of the ovaries during 
radiation therapy should be considered standard of care, when ovaries are not in the treatment field. 
2.2.5. Decision Making 
Making decisions about fertility preservation requires sufficient information and the time to weigh 
the benefits and limitations of the proposed procedures. As noted above discussions between medical 
teams and patients/parents are still not routine practices. Anderson et al. examined how frequently 
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physicians of children and adolescents diagnosed with cancer discussed fertility preservation and how 
often referrals were made. Prior to therapy a discussion on risk for fertility was had with 86% of post 
pubertal females, fertility preserving techniques were discussed with 13% of females and 4 patients 
(1%) were referred to a fertility specialist [57]. Low level of referrals may reflect the barriers related to 
timing and cost for established methods of fertility preservation in females and/or concern about 
experimental procedures but a recent small, qualitative study by Peddie et al. offers some insight into 
how the physician/patient interaction may affect decision making and referrals. Fifteen medical 
professionals and 18 female cancer patients aged 17–45 were interviewed. Medical professionals were 
less likely to have detailed discussions with women than with men and took many more individual 
factors (age, current parental status, and likelihood of relapse) into account when deciding how much 
information to provide. Women felt that pursuing fertility preservation options was discouraged and 
that conversations strongly emphasized the risk of delaying therapy. They perceived that individual 
factors were being taken into account in terms of how much information they were given, and they felt 
that they were not given the opportunity to have an adequate discussion to help make their decision [20]. 
This data suggests that additional research is needed to explore the content of the discussions being 
had and what information patients and parents need in order to make informed decisions [58], 
particularly as technologies improve. 
2.3. Considerations Post-Therapy 
After therapy has been completed patients exposed to potentially gonadotoxic therapies should have 
their ovarian function monitored. Traditionally, assessment of diminished ovarian function has relied 
upon sustained cessation or irregularities in the menstrual cycle as well as persistent elevations in follicle 
stimulating hormone (FSH) indicating proximity or achievement of menopause, with accompanying 
infertility. In this setting, further evaluation by an endocrinologist is warranted, particularly as early 
ovarian failure may increase the risk for the development of osteoporosis and cardiovascular disease [29]. 
Patients who received gonadotoxic treatment when they were pre-pubertal may be at risk of delayed or 
absent pubertal development which also requires further evaluation and intervention. 
Amenorrhea, both during and after therapy, is not uncommon in post-pubertal females. Those 
females who resume regular menstrual cycles following the completion of cancer directed therapy may 
still be at risk of developing premature menopause. Increasingly Anti-Mullerian hormone (AMH), 
which can be measured in the serum, has been utilized to provide earlier information about ovarian 
reserve [59,60]. Cross sectional studies of childhood cancer survivors compared with healthy controls 
have shown lower levels of AMH many years after the completion of therapy [61]. Currently, the 
Children’s Oncology Group recommends that survivors at risk for infertility (defined above) be 
screened with measurements of LH, FSH and estradiol at age 13 and then as clinically indicated [27]. 
Referrals to a reproductive endocrinologist should be initiated for survivors with signs of or an in 
interest in evaluating ovarian reserve. Unfortunately, even with the addition of AMH and ovarian 
imaging modalities it is not possible to estimate time to menopause and thus the remaining duration of 
the reproductive window in a given individual. Therefore, oocyte or embryo cryopreservation 
following completion of therapy may allow for preservation of fertility preservation in those 
individuals at risk of premature menopause but not ready to become pregnant. 
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It is encouraging to note that, even in the setting of diminished ovarian reserve [62] or clinical 
infertility [63], pregnancy is achievable in the survivor population. When needed, previously 
cryopreserved embryos or oocytes can be thawed, (and fertilized with partner or donor sperm in the 
setting of oocyte cryopreservation), and transferred into the uterus following adequate hormonal 
stimulation to prepare the uterus for implantation. For those survivors who are infertile, did not 
preserve embryos or oocytes but who want to carry a pregnancy, donor eggs with either partner sperm 
or donor sperm may be an option. When a survivor is not able to carry a pregnancy either because she 
has had a hysterectomy, has had sufficient radiation therapy to cause uterine insufficiency or requires 
ongoing imaging that would subject a fetus to radiation, gestational surrogacy, that is the use of the 
uterus of another female, offers the opportunity for a biological child [9]. Gestational surrogacy is not 
universally legal; it is regulated very differently in different countries, and on the state level in the 
United States, so awareness of laws and procedures in a given area is critical for success. When 
options for biologic parenthood are unavailable or undesirable, adoption remains a possibility for 
parenthood. Ascertaining the policies of a given adoption agency or country of adoption is necessary 
as there can be variable policies with regard to those who have had a history of cancer. 
2.4. Risk for Infertility in Males 
Spermatogenesis, the maturation of spermatogonia from spermatogonial stem cells (SSC), begins  
in puberty and then continues through a male’s lifetime, as the SSC are also self-renewing. The  
process, which takes approximately 74 days, is regulated by hormones secreted from the  
hypothalamic-pituitary-testicular axis. Therefore, unlike females, males do not face a defined 
reproductive window unless they sustain a very significant insult to the population of SSCs. While 
sperm quality may change over time, males continue to be able to have biologic children well into 
older adulthood [64]. 
As rapidly differentiating cells, spermatogonia are particularly sensitive to chemotherapy and 
radiation. Post pubertal males commonly experience temporary azoospermia during therapy that may 
persist for a number of years post therapy [65]. Since SSC cells proliferate at a slower rate than 
spermatogonia they are less vulnerable to effects of gonadotoxic therapy but can be affected 
nonetheless [66]. Permanent azoospermia therefore depends on the degree to which SSC are depleted; 
it is this mechanism that explains why pre-pubertal males are also at risk of permanent azoospermia [67]. 
Sexual function, i.e., the ability to maintain an erection and ejaculate, can also be affected by 
chemotherapy and can contribute to the ability for males to father children through intercourse. 
Finally, surgical interventions that result in disruption of the anatomy or nerves supplying the 
reproductive organs may limit unassisted reproduction. 
Alkylating agents such as cyclophosphamide, ifosfamide, procarbazine, and busulfan as well as 
cisplatin have been shown to be highly gonadotoxic, in a dose dependent fashion [68]. The testes are 
extremely sensitive to even low doses of radiation. Toxicity and time to recovery is dose dependent 
with higher doses leading to permanent azoospermia. Doses as low as 0.1 Gy to the seminiferous 
tubules can cause short term azoospermia. Longer term azoospermia with recovery after approximately 
30 months can be seen in the 2–3 Gy range while doses of 6 Gy and greater can lead to permanent 
infertility by causing significant depletion of the SSC pool [69]. The COG long term follow-up guidelines 
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define exposure to MOPP therapy ≥3 cycles, busulfan ≥600 mg/m2, cyclophosphamide ≥60 g/m2, 
multiple alkylating agents, any alkylator combined with testicular irradiation, pelvic irradiation or TBI, 
and radiation doses in the range of 3–6 Gy as risks for the development of oligospermia/azoospermia [70]. 
Prior to the onset of therapy azoospermia may be present in certain populations including patients with 
Hodgkin lymphoma [71] and testicular cancer [72]. 
2.5. Options for Fertility Preservation 
2.5.1. Sperm Banking 
Preservation of fertility in post pubertal males is reliably accomplished by cryopreserving sperm 
prior to the onset of gonadotoxic therapy. This timing is important as there is the possibility that 
chromosomal damage can occur when the collected sperm has been exposed to gonadotoxic therapy [73]. 
The most common method to obtain sperm is through masturbation, which can be done in the in-patient 
or out-patient setting, or via referral to a sperm bank. Males who are greater than Tanner stage III 
should be physically mature enough to masturbate to ejaculation. Optimal procedures for the collection 
of sperm include abstinence 48 h prior to collection and the collection of multiple specimens, at least 
24 h apart [74]. The semen sample is evaluated for sperm count, morphology and motility prior to 
cryopreservation. Depending on the volume, multiple vials of sperm can be cryopreserved. The sperm 
is thawed when needed for use in future assisted reproduction techniques. Sperm cryopreserved for as 
long as 28 years has shown to be viable when thawed [75]. It is advisable that all males Tanner 
Stage III or greater attempt sperm banking prior to the initiation of therapy, even if they are not 
receiving gonadotoxic therapy. The rationale for this is that most males undergo a period of 
azoospermia following the completion of therapy and the face of a relapse and more toxic therapy may 
be unable to sperm bank at that time [76]. 
Limitations to this form of cryopreservation are related primarily to an inability to masturbate, 
whether secondary to age, illness, discomfort [77] or cultural mores that prohibit masturbation. 
Emotional and practical issues may also be present that limit success. Adolescent males may be 
uncomfortable and embarrassed discussing masturbating. If sperm banking occurs in the clinic or 
hospital, it is essential that a private area be designated, and the adolescent assured that he will not be 
interrupted. If an adolescent will be banking at a sperm bank facility, it may be necessary to ensure that 
the facility itself has age appropriate space and material available [78]. 
Alternative approaches exist when masturbation is not possible. Electroejaculation (EEJ) involves 
the placement of a transrectal probe while the patient is under general anesthesia. Electrical stimulation 
is applied until ejaculation occurs and sperm is collected [79]. Sperm retrieval rates with EEJ average 
around 60% in the adolescent population [79,80]. If low sperm counts or obstructive azoospermia is 
present, sperm may also be acquired via microsurgical epididymal sperm aspiration, the aspiration of 
sperm from the epididymal tubule; or testicular sperm extraction (TESE). These procedures are 
invasive and require anesthesia but they can be combined with other surgical procedures. Sperm 
extracted from testicular tissue or the tissue itself can be processed and cryopreserved. 
Ideally, the development of a relationship between an oncology program and a designated sperm 
bank can streamline the process for a given patient as time constraints related to starting therapy are 
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often cited as an obstacle to sperm banking [81]. With a system in place to coordinate the requirements 
of sperm banking including paperwork, laboratory evaluation and finances, the process itself takes a 
relatively short period of time and should not delay therapy. Studies have demonstrated that sperm 
banking is feasible in the adolescent population [82,83]. 
2.5.2. Testicular Tissue Cryopreservation 
Sperm banking is not possible for pre-pubertal boys as they cannot yet produce mature 
spermatozoa. Cryopreservation of testicular tissue that contains SSC offers an experimental option for 
preservation of fertility in pre-pubertal boys and post-pubertal males who cannot produce a sperm 
sample [84]. Currently, there are no human applications for the use of thawed testicular tissue. 
Research is ongoing in animal models to develop maximally effective methods of freezing, thawing 
and transplanting this tissue [85,86]. A noteworthy shortcoming with testicular tissue transplantation 
even with improvements in technology is the potential to re-introduce malignant cells [87]. Research is 
also underway to evaluate methods to mature and expand SSCs in vitro so that they could be used with 
assisted reproduction techniques and to evaluate the acceptability, feasibility and safety of testicular 
tissue biopsies in young, newly diagnosed pediatric cancer patients [88]. 
2.5.3. Protection of the Testes during Treatment 
The testes should be shielded during radiation therapy to try to minimize the exposure to scatter 
radiation. Consideration can also be given to moving the testes out of the radiation field. At this time, 
there are no medications shown to protect males from gonadotoxicity [11]. 
2.5.4. Decision Making 
As stated in the introduction, males are often more satisfied with the information that they receive 
about fertility preservation prior to the initiation of therapy and much higher referral rates occur than 
for females [57]. In the small qualitative study by Peddie et al. referenced above both males and 
medical professionals recalled that fertility conversations at diagnosis generally encouraged sperm 
banking, even if the face of low risk for infertility, and was presented as a straight forward 
intervention, regardless of individual demographic factors [20]. Despite being more satisfied with the 
information that they are receiving about fertility preservation options prior to the start of therapy, 
males still underutilize sperm banking at diagnosis and cryopreserved sperm post therapy but rarely 
dispose of sperm [89]. Characteristics associated with sperm banking are younger age, better 
education, being childless, being single, having a higher quality of life, and being optimistic. The 
single most important reason was a desire to have children in the future [90]. Oncologists who advise 
patients to pursue sperm banking appear to have a role in increasing rates [91]. Deterrents to sperm 
banking include concerns about delaying therapy and worries about the consequences of children 
conceived from frozen sperm [89]. The latter in particular suggests that taking the time to understand, 
and possibly correct, the perceptions patients have about sperm banking is a critical component to 
fertility preservation discussions. 
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With regard to testicular tissue banking, Ginsberg et al. studied the factors involved in making a 
decision to cryopreserve testicular tissue among 74 patients, 12 years old or younger, and their parents 
who were approached to undergo this procedure. Fifty seven families consented and 48 boys had a 
biopsy performed. The researchers found that although diagnosis was a stressful time, they were able 
to consider the experimental nature of the procedure. Of note, those that did consent to biopsy felt less 
overwhelmed than those that refused. In those families where a biopsy was performed there was an 
expression of hopefulness for future scientific advances, a stronger desire to maintain the capacity for 
biologic offspring for their son and a hope to minimize distress if infertility did occur. For those that 
chose not to consent concern about the risk of the biopsy was cited as a reason [88]. 
2.6. Considerations Post Therapy 
Predictions about which patients will become infertile following gonadotoxic therapy remains 
imprecise and exposed males may still retain sufficient fertility to sire a child through sexual 
intercourse [4]. The CCSS has reported a prevalence of infertility in 46% of male survivors compared 
to 17.5% in the sibling cohort [92]  and a decreased hazard ratio of 0.56 (95th percent confidence 
interval 0.49–0.63) for fathering a pregnancy compared to sibling controls [3]. However, within the 
CCSS cohort 37% of males defined as infertile were still able to have biologic children. The authors 
suggest that this may point to episodic periods of infertility and fertility[92] . Although it would be 
desirable to have serum screening markers for infertility recent evidence suggests that FSH and 
inhibin B may not be suitable replacements for semen analysis in the evaluation of sperm 
viability [93]. Testosterone levels may provide information about pubertal status, hypogonadism and 
sexual functioning with decreased levels indicating prepubertal status, hypogonadism or possible 
sexual dysfunction [94]. 
Assisted reproduction offers options for biologic children for men with very low sperm counts 
(oligospermia) via a technique known as intracytoplasmic sperm injection (ICSI), the injection of a 
single sperm into an oocyte. ICSI greatly improves the likelihood that a small number of viable sperm 
retrieved pre or post therapy can be used for fertilization. In survivors, banked sperm can be thawed for 
use with in vitro fertilization (IVF) with or without ICSI. Pregnancy rates using this methodology are 
similar to those in the general population [95], and the incidence of congenital anomalies is also not 
significantly different from those not treated for cancer [96,97]. Yet, despite the opportunities that 
assisted reproduction offers males, they often do not follow up with assessments of their fertility or use 
of frozen sperm. It is not clear whether this is due to having sired a child via sexual intercourse, 
distress about confirming they are infertile, not receiving information about follow-up post treatment 
or not comprehending the full implication of sperm banking given at diagnosis [98]. When viable 
sperm is truly unavailable, male survivors can also consider using donor sperm for fertilization of a 
partner’s oocytes. As with females, adoption is also an option for creating a family. 
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Figure 1. Algorithm of fertility preservation options for males. 
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Figure 2. Algorithm for fertility preservation options in females. 
 
3. Conclusions 
With excellent survival rates and advances in the field of reproductive endocrinology, discussing 
risks for infertility and fertility preservation options with pediatric and adolescent patients diagnosed 
with cancer at diagnosis is an important component of comprehensive care. Even though such 
discussions are limited by inexact estimates of risks and reproductive technologies, early discussions 
allow patients and families to engage in decisions and may decrease the potential for regret later on. 
Discussion of fertility preservation should not be limited to diagnosis; survivorship is also an important 
time for patients to be aware of their fertility status and choices. For girls it is particularly important to 
monitor ovarian reserve as they have the potential to avail themselves of fertility preservation 
interventions post therapy. Algorithms for consideration of fertility preservation practices are provided 
for females and males in Figures 1 and 2 respectively.  
Despite an acknowledgement that discussions of fertility are important they do not occur routinely, 
yet these discussions are vital to help patients and families make decisions about fertility preservation. 
Understanding the risks for gonadal toxicity and options for fertility preservation are only the first 
steps to improving the likelihood that these discussions take place. Developing routine institutional 
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practices and infrastructure is necessary given the time constraints and multiple stressors that exist at 
the time of diagnosis. The type of program that suits an individual institution may vary depending on 
the size and complexity of the practice but needs to include a mechanism that triggers identification of 
the target population, provides patients and families with information and facilitates access to services. 
The ability to consistently provide patients and families with up to date information in a timely fashion 
is likely to be beyond the scope of an individual physician. Identifying or creating reliable and relevant 
supplemental information, or directing patients to cancer focused websites is critical as information 
available by a patient initiated search may be inadequate and confusing especially at the time of a new 
diagnosis [99]. Development of fertility preservation programs, partnerships between pediatric 
oncology and reproductive endocrinology programs, and use of electronic medical records can help 
stream line the process of discussing and referring patients for fertility preservation [100,101]. These 
measures should be in place throughout the survivorship lifespan, from diagnosis to long term follow-up. 
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